MOODY’S-ANALYTICS
Moody’s Analytics, a global provider of financial intelligence, announced today that its software has been selected by Danish pension fund, Lægernes Pension. Lægernes Pension will be using the Moody’s Analytics Scenario Generator for Solvency II liability valuation, stress testing, and scenario analysis.
The Moody’s Analytics Scenario Generator is an award-winning simulation framework clients deploy for actuarial reporting, risk and capital calculation and analysis, and investment and ALM analysis.
Lægernes Pension will also take advantage of the Moody’s Analytics Scenario Generator Automation Module, allowing the organization to streamline its modeling processes. By automating model set-up, execution, and validation, both scenario production timelines and costs can be reduced.
“Amidst economic uncertainty, insurers globally are looking for ways to manage their risk effectively, and to understand the sensitivity of their liabilities to different risk factors,” said Colin Holmes, Managing Director at Moody’s Analytics. “We are delighted that Lægernes Pension has selected our Scenario Generator and automation software to inform their risk-based decision-making and strengthen their risk management processes.”
“The Moody’s Analytics Scenario Generator, in conjunction with the automation functionality, combines the software and support required to undertake a range of asset-liability modeling activities including Solvency II liability valuation,” said Ulrik Eltang Høgh, Chief Risk Officer at Lægernes Pension. “More broadly, the Moody’s Analytics solution will form an integral part of our overall risk management framework.”
Earlier this year, Moody’s Analytics won five categories at the 2020 InsuranceERM Awards, including Best Economic Scenario Generator Software of the Year.
Learn more about the Moody’s Analytics Scenario Generator.
About Moody’s Analytics
Moody’s Analytics provides financial intelligence and analytical tools to help business leaders make better, faster decisions. Our deep risk expertise, expansive information resources, and innovative application of technology help our clients confidently navigate an evolving marketplace. We are known for our industry-leading and award-winning solutions, made up of research, data, software, and professional services, assembled to deliver a seamless customer experience. We create confidence in thousands of organizations worldwide, with our commitment to excellence, open mindset approach, and focus on meeting customer needs. For more information about Moody’s Analytics, visit our website or connect with us on Twitter or LinkedIn .
Moody's Analytics, Inc. is a subsidiary of Moody's Corporation (NYSE: MCO). Moody’s Corporation reported revenue of $4.8 billion in 2019, employs approximately 11,300 people worldwide and maintains a presence in 40 countries.
About Lægernes Pension
Lægernes Pension is a Danish pension fund that manages labor market pensions for 46,000 Danish Medical Doctors. On their behalf Lægernes Pension invest approximately DKK 100 billion.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200520005327/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Tecnotree Maintains Momentum with Sixth Consecutive Quarter of Profit and Cash Flow29.10.2025 10:12:00 CET | Press release
Tecnotree, a global digital platform and services leader for AI, 5G, and cloud-native technologies, announced today its Q3 2025 results, summarizing financial performance year-to-date ending 30 September 2025. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251029815979/en/ Tecnotree Maintains Momentum with Sixth Consecutive Quarter of Profit and Cash Flow Year-to-Date Financial Highlights as of Q3 2025: Positive free cash flow EUR 3.2 (–2.2) million, sixth consecutive quarter of cash-positive operations. Revenue in constant currency EUR 56.6 (54.0) million, +4.8%. EBIT in constant currency EUR 14.9 (13.0) million, +15.0%. Annual recurring revenue EUR 25.1 (23.2) million, +8%. Order backlog EUR 105.5 (75.1) million, +40%. Commenting on the results for the third quarter of 2025, Padma Ravichander, CEO of Tecnotree, says: “Tecnotree’s Q3 2025 results reflect our disciplined focus on profitable order book execution, with year-to
Domaine Worldwide and Shopify Launch Enterprise Platform Migration Initiative Across Europe29.10.2025 10:00:00 CET | Press release
Domaine Worldwide, the leading global Shopify design and development partner, announced the launch of its European Platform Migrations partnership with Shopify today. The initiative positions Domaine as the go-to commerce partner for enterprise-level brands across the UK, DACH, and BENELUX regions looking to migrate to Shopify’s scalable, commerce-ready infrastructure. As enterprise organizations across Europe face the challenge of modernizing legacy systems, this campaign highlights the combined power of Domaine’s migration expertise and Shopify’s enterprise-grade flexibility—offering brands a seamless path to improved performance, agility, and long-term growth. “For enterprise retailers, platform migration is no longer just a technical decision—it’s a strategic one. For some, it's become a strategic imperative,” said Marko Bon, Co-founder and President of Domaine. “We’ve seen first-hand how a migration to Shopify is a foundational step in digital business transformation, unlocking st
MOPIC Unveils 32-Inch Autostereoscopic 3D Display for Endoscopic and Microscope Applications Capable of Realistic Depth and Immersive Visualization29.10.2025 09:00:00 CET | Press release
MOPIC, a leading developer of autostereoscopic 3D display technology, has unveiled its 32-inch autostereoscopic 3D display designed for 3D endoscopic and microscope imaging systems. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251029144650/en/ MOPIC unveiled its 32-inch autostereoscopic 3D display capable of lifelike depth and spatial perception without the need for 3D glasses (Photo: MOPIC) The new product reproduces lifelike depth and spatial perception without the need for 3D glasses, setting a new benchmark for medical visualization and education. Optimized 3D Solution for Medical Training and Research The 32-inch autostereoscopic 3D display combines a display with an integrated 3D lens, an eye-tracking camera, and real-time 3D rendering software provided as an SDK. It supports standard stereo formats such as Side-by-Side, and can be directly connected to existing endoscopes or microscope systems through 3D software in
NEC to Acquire CSG, Strengthening Its Position as a Global Leader in Digital Transformation29.10.2025 08:44:00 CET | Press release
NEC Corporation (TSE: 6701) (“NEC”) and CSG Systems International, Inc. (NASDAQ: CSGS) (“CSG”) today announced they have entered into a definitive agreement under which NEC will acquire CSG for US$80.70 per share in cash, for a total enterprise value of approximately US$2.9 billion, or JPY438.5 billion, including debt. The transaction price represents a 17.38% premium over CSG’s closing price of US$68.75 on October 28, 2025, and a 23.07% premium to the volume-weighted average price (VWAP) of CSG common stock for the 30 days ending October 28, 2025. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251029203825/en/ The transaction strengthens NEC's position as a leader in next-generation digital solutions and accelerates AI and cloud-driven innovation for customers across industries. It will bring together complementary software and services across digital transformation, expanding NEC's software-as-a-service (SaaS) portfolio, c
Samsung Bioepis to Commercialize BYOOVIZ® (ranibizumab) in Europe from January 202629.10.2025 08:00:00 CET | Press release
Samsung Bioepis will assume full commercial responsibility for BYOOVIZ® (ranibizumab) upon full transition of Biogen’s commercialization rights back to Samsung Bioepis effective as of January 2026BYOOVIZ, approved by the European Commission (EC) in August 2021 as the first ophthalmology biosimilar in Europe, has been commercially available in several European countries since March 2023 Samsung Bioepis Co., Ltd. announced today that the company has entered into an Asset Purchase Agreement (APA) with Biogen regarding Samsung Bioepis’ two ophthalmology assets: BYOOVIZ® (ranibizumab), a biosimilar referencing Lucentisi (ranibizumab) and OPUVIZ™ (aflibercept), a biosimilar referencing Eyleaii (aflibercept) — in Europe. Samsung Bioepis will have full responsibility for commercialization of BYOOVIZ upon the transfer of commercial rights from Biogen back to Samsung Bioepis, effective as of January 2026. “We are pleased to announce our direct commercialization initiative for BYOOVIZ in Europe.
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom